Montana’s $12,500 fast track for unproven drugs is now open for business
MIT Technology Review · Jul 31, 2026 · 2 min read
If you’ve got a biotech startup, a drug that’s cleared Phase 1 safety testing in maybe a dozen people, and $12,500, Mon...
4 articles
Explore our coverage of drug-development — 4 curated articles, summaries, and related resources from the Inblix archive.
MIT Technology Review · Jul 31, 2026 · 2 min read
If you’ve got a biotech startup, a drug that’s cleared Phase 1 safety testing in maybe a dozen people, and $12,500, Mon...
MIT Technology Review · Jul 31, 2026 · 2 min read
Kris DeVault is watching his son Brody miss the most critical years of brain development. At three years old, Brody has...
OpenAI Blog · Jul 17, 2026 · 2 min read
Two months. Seven hundred and fifty custom GPTs. Moderna's partnership with OpenAI isn't a press release gimmick—it's a...
OpenAI Blog · Jul 16, 2026 · 3 min read
Genmab isn't dabbling in AI — the Danish biotech has gone all-in, scaling ChatGPT Enterprise from a 1,000-employee pilo...